Bayer Advances 225Ac-PSMA-Trillium for Metastatic Prostate Cancer

New Data Supports Next-Phase Development of Targeted Alpha Therapy Why is the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) so challenging? Despite significant advances, the prognosis for men with mCRPC remains poor, with a median survival of about 31…










